Sleep Problems in Children with Fetal Alcohol Spectrum Disorders

Maida Lynn Chen, M.D.1; Heather Carmichael Olson, Ph.D.2; Joseph F. Picciano, M.S.3; Jacqueline R. Starr, Ph.D.4; Judith Owens, M.D., M.P.H.5

Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington School of Medicine, Seattle, WA; Department of Psychiatry and Behavioral Sciences, Division of Child Psychiatry, University of Washington School of Medicine, Seattle Children's Hospital Research Institute, Seattle, WA; Seattle Children’s Hospital Research Institute, Center on Child Health, Development and Behavior, Seattle, WA; The Forsyth Institute, Cambridge, Massachusetts and University of Washington School of Public Health, Seattle, WA; Division of Pulmonary and Sleep Medicine, Children’s National Medical Center, Washington, DC

Study Objectives: Sleep problems in children with fetal alcohol spectrum disorders (FASD) are reportedly common but not well characterized. Objectives were to: (1) assess sleep concerns in children with FASD using a caregiver-report survey, the Children’s Sleep Habits Questionnaire (CSHQ); (2) compare CSHQ results with those of previously reported community sample; and (3) describe pilot polysomnography findings in children with FASD.

Methods: Children with FASD were recruited from a behavioral intervention study, and participating caregivers completed the CSHQ. CSHQ results were compared with the original data from a previously published community sample of similar age. Participants with FASD and elevated CSHQ scores were offered overnight polysomnography.

Results: Thirty-three children with FASD (4.1-12.1 years) were enrolled; 85% of children with FASD scored above the clinical cutoff Total Score of 41, reflecting marked sleep disturbance. Elevated subdomain scores occurred primarily in areas concerning for pediatric insomnia. Those with comorbid ADHD had elevated CSHQ on additional subdomains with no difference in Total Scores. Compared with the community sample, children with FASD had higher Total Scores on the CSHQ (52 vs. 39, p < 0.001). Polysomnography, completed in 5 subjects, revealed mild sleep disordered breathing and fragmented sleep with elevated non-respiratory arousal indices.

Conclusions: Clinically significant sleep problems are present in children with FASD on both subjective and objective measures. Further investigation is needed to better describe these sleep disturbances and their impact on overall health and daytime neurobehavioral problems in this clinical population.

Keywords: sleep disorders; fetal alcohol spectrum disorders; prenatal alcohol; pediatric insomnia; school-age children; fetal alcohol syndrome; maternal pregnancy drinking

Citation: Chen ML; Olson HC; Picciano JF; Starr JR; Owens J. Sleep problems in children with fetal alcohol spectrum disorders. J Clin Sleep Med 2012;8(4):421-429.
insomnia, periodic limb movement disorder, sleep disordered breathing, and increased daytime sleepiness on multiple sleep latency tests compared to controls. Improvement or resolution of ADHD symptoms with treatment of insomnia or other underlying sleep disorder has been reported.

Despite the demonstrated link between sleep problems and daytime difficulties in typically developing and other clinical populations, few studies have directly addressed sleep problems in those with FASD. Only one study has been published performing multidimensional assessment of sleep and daytime problems in FASD using standardized measures. Indeed, higher rates of both sleep and sensory problems were found in those with FASD compared to controls in that study. However, these findings need to be replicated in other cohorts. Many of the health, behavioral, and neurocognitive manifestations of pediatric sleep disturbance are conditions that are also known to be common problems among those with FASD. If a connection between sleep problems and daytime function can be established in FASD through further studies, proven effective treatments for these sleep disorders could be implemented in children with FASD. Such treatments could provide lifelong benefit for children with FASD, including reduction of health care and societal costs.

The primary goal of this research was to begin building a comprehensive profile of sleep problems in this remarkably prevalent, but under recognized clinical population of children with FASD. Thus, study aims were as follows: (1) to systematically describe parent-reported sleep habits in a representative group of children with FASD by using the Children’s Sleep Habits Questionnaire (CSHQ); (2) to compare these results to CSHQ results from a previously described community sample; and (3) to obtain pilot and feasibility data from polysomnography (PSG) sleep assessment within a subgroup of the children with FASD. The authors hypothesized that children with FASD would show a higher rate of clinically concerning sleep problems on the CSHQ, compared with profiles of a typically developing community sample.

**METHODS**

**Participants**

**Children with FASD**

Thirty-three children were recruited from 34 participants enrolled in a behavioral intervention research study or related intervention training study in 2007. All participants enrolled in this subject pool were diagnosed with conditions within the umbrella category of FASD. All 34 families agreed to be enrolled, but one participant did not complete a sleep questionnaire and was therefore ineligible for the current descriptive study. All children in the subject pool were seen by an interdisciplinary team within the Washington State Fetal Alcohol Syndrome Diagnostic and Prevention Network (FAS DPN), and received a formal diagnosis on the fetal alcohol spectrum. Of the 33 participants, 88% had clinically significant externalizing behavior or attention problems on the Child Behavior Checklist (CBCL), which are common difficulties among children with FASD. Eligibility for the current study included a diagnosis on the fetal alcohol spectrum with confirmed alcohol exposure based on the clinically reproducible 4-Digit Diagnostic Code (see below); registration in a clinical database of a statewide network of FASD diagnostic clinics; residence in a designated geographic catchment area in Washington State; aged 4 to 12 years at time of enrollment; and residence with the current caregiver for at least the next 1.5 years to maximize retention in the larger behavioral intervention study.

Exclusion criteria for the larger study included other birth defect syndromes; known seizure disorder requiring daily medications; IQ < 55; diagnosed thought disorder; very serious conduct problems (e.g., fire-setting); and current primary caregivers with alcohol abuse. Potential participants for both studies were not recruited based on any pre-study sleep assessments. Research was approved by the Institutional Review Boards (IRB) of the Seattle Children’s Research Institute and Washington State Department of Social and Health Services, with further approval for comparison with de-identified community control data.

The 4-Digit Code is a standardized method for characterizing conditions across the fetal alcohol spectrum by using 4-point Likert scales to characterize 4 primary categories of definitional criteria. Higher scores indicate features in each category that are more similar to their classic representation in full FAS. These 4 categories include: (1) growth deficiency; (2) characteristic facial features; (3) central nervous system damage or dysfunction; and (4) level of prenatal alcohol exposure. Code combinations are collected into broader diagnostic categories, such as FAS or partial FAS. Non-FAS conditions seen in this study on the wider spectrum are grouped together as “static encephalopathy, alcohol-exposed” and “neurobehavioral disorder, alcohol-exposed” which other diagnostic systems may categorize as “alcohol-related neurodevelopmental disorders.”

**Representativeness of Sample with FASD**

Because participants with FASD were recruited from a behavioral intervention study, care was taken to ascertain whether this sample of participants reflected the larger FASD population. Demographics, behavior profiles on the CBCL, comorbid ADHD diagnoses and diagnoses on the fetal alcohol spectrum were compared between this sample and the much larger Washington State FASD clinical database.

**Community Sample**

As part of a separate, already concluded study, comparison data were drawn from a large community sample (n = 418) of typically developing children, aged 4-11 years, enrolled in any of 3 public elementary schools during the 1997-98 academic year. Sample characteristics and study methods for this community sample have been fully reported elsewhere, though original data on individuals were used for this study’s analyses. The community sample study was conducted to validate the CSHQ, so data were used in the current study only for descriptive comparison. The original community sample research project was approved by the IRB of Lifespan Hospitals, with further approval for current comparison to participants with FASD.
Measures

Demographic Data

Demographic information included children’s age, caregiver report of race/ethnicity, and gender. Family characteristics included measures of socioeconomic status (SES) based upon the Hollingshead Index and family structure (e.g., whether there was a father in household). Information on chronic medical conditions and medications was obtained via parent report as medical records were not consistently available. For participants with FASD, diagnostic category on the fetal alcohol spectrum was ascertained from clinical records.

Sleep Habits

Children’s sleep habits were subjectively assessed by using the CSHQ, a validated 33-item caregiver questionnaire. The CSHQ includes key sleep domains grouped into 8 subscales: (1) Bedtime Resistance; (2) Sleep Onset Delay; (3) Sleep Duration; (4) Sleep Anxiety; (5) NightWakeings; (6) Parasomnias; (7) Sleep Disordered Breathing; and (8) Daytime Sleepiness. Most CSHQ items are rated on a 3-point scale ranging from “usually” (5 to 7 times/week) to “sometimes” (2 to 4 times/week) to “rarely” (0 to 1 time/week). Two questions about daytime sleepiness are rated on a 3-point scale of “not sleepy,” “very sleepy,” or “falls asleep.” Excluding 2 items that were included in multiple subscales, the subscale inter-correlations for the community control group were $r = 0.19$. The Total Score sums all 33 items, and higher values indicate more disturbed sleep. A Total Score ≥ 41 has a sensitivity of 80% and specificity of 72% for differentiating between groups of children with and without sleep disorders diagnosed by a sleep medicine specialist.

Polysonomography

Referral for a sleep medicine consultation and PSG was offered to participants with FASD whose CSHQ scores exceeded the clinical cutoff (≥ 41). Consent was obtained to review medical records, including the sleep evaluation and PSG findings. Sleep medicine consultation and PSG were arranged by families (not study personnel), and not all families chose to pursue this evaluation.

Each PSG lasted ≥ 6 h and was performed in an accredited pediatric-specific sleep laboratory setting, which included a private darkened room free of distraction with a parent or guardian present. The following physiologic parameters were monitored: electroencephalogram, electro-oculogram, submental and anterior tibialis electromyograms, electrocardiogram, oronasal airflow measured by thermistor and pressure transducer, expired end-tidal carbon dioxide, oxygen saturation via pulse oximeter, and thoracic and abdominal movement. All data were recorded into a computer-based acquisition and analysis program (Rembrandt, Buffalo, NY), scored by one certified technician, and interpreted by a board certified sleep medicine physician in accordance with American Academy of Sleep Medicine (AASM) guidelines.

Sleep architecture, including sleep stages, cortical arousals, awakenings, limb movements, and arousal indices were assessed by standard techniques. Respiratory disturbances were defined as follows: (1) Obstructive apnea: ≥ 80% reduction in airflow for 2 respiratory cycles in the presence of continued thoracic/abdominal effort; (2) Hypopnea: 30% to 79% reduction in airflow for 2 respiratory cycles, accompanied by an EEG cortical arousal, awakening, and/or ≥ 3% oxygen desaturation; (3) Central apnea: ≥ 80% reduction in airflow with no respiratory effort, lasting ≥ 2 respiratory cycles, and accompanied by an EEG arousal, awakening, and/or ≥ 3% oxygen desaturation. The apnea hypopnea index (AHI) was defined as the total number of respiratory disturbances averaged per hour of total sleep time, and further divided into those caused by obstructive apneas/hypopneas and those caused by central apneas.

Both attendant technician and interpreting physician were blinded to the CSHQ score and any involvement in an FASD intervention study, but given the clinical setting and behavioral considerations of the participants, could not be blinded to an underlying diagnosis of FASD in order to optimize patient safety and likelihood of successful data acquisition.

Data Analysis

For this exploratory study, descriptive statistics are reported using mean ± standard deviation (SD) for normally distributed parameters or median with interquartile range (IQR) for those with skewed distributions. Because the fundamental aims focused on the CSHQ scores, formal comparisons were run only on CSHQ scores between the study and community sample groups for which raw data were available. Comparisons were carried out by using unpaired $t$-tests with 2-sided $p$-values and significance set at $p < 0.05$. Correction for multiple comparisons was not used in this exploratory study. Age, gender, SES, family structure, and presence of ADHD or other medical problems were found to vary by participant group, but none were found to correlate with CSHQ Total Score, so statistical adjustments for these factors were not performed in this pilot study. Preliminary evaluation for associations between and within CSHQ scores and markers of FASD severity was accomplished by using linear regression. All statistical analyses were performed using Stata, version 10 (College Station, TX).

For descriptive purposes, the group with FASD was further divided into those with and without caregiver report of ADHD for further descriptive comparison. Group characteristics of the community sample and larger Washington State FASD sample are provided for the reader’s reference but were not statistically compared with this study’s participants, given methodologic differences in original data collection.

Given the small number of children with PSG data, we report PSG parameters only as descriptive statistics, with published normative data from 388 typically developing children with a mean age of 6.8 ± 0.48 years (range 6.0-8.6 years) provided for reference.

RESULTS

Sample Characteristics

Demographics

Within the group with FASD, mean age was 7.5 ± 2.2 years, with a slight predominance of males (Table 1). Fifty-eight percent were in adoptive families and 12% in foster families, while 18% of participants were living with one or both birth parents.
This was an ethnically diverse sample, with 61% reported as Caucasian/White, 9% African American, 6% Hispanic, 6% Native American, and 18% reported to be “mixed race.” Two participants had diagnoses consistent with the full FAS (6%), 3 with partial FAS (9%), 7 with “static encephalopathy/alcohol-exposed” (21%), and the remaining 64% with “neurobehavioral disorder/alcohol-exposed.” When compared to the community sample, the group with FASD was of similar age but had more males, less paternal presence in the household, and lower mean SES (Table 1).

### Caregiver Report of ADHD

The study group with FASD had higher rates of caregiver-reported ADHD when compared with the community sample, in which children who were taking psychostimulant medications (presumably for ADHD) were excluded for purposes of the original CSHQ validation study design (Table 1). 21

### Representativeness of FASD Group

The current study’s FASD group is broadly representative of those found in the FAS DPN clinical database, which at the time of study enrollment included 1729 patients enrolled from 1993–2005. 22,23 Sixty-one percent of the FAS DPN patients fell into the 4- to 12-year age range. Demographic, behavioral, and diagnostic characteristics of both the study and larger FAS DPN groups are similar, indicating that the current study cohort is reasonably representative of the larger WA State FASD database (Table 2).

### Subjective Sleep Assessment

#### CSHQ

Caregivers of children with FASD reported higher levels of sleep complaints, with a mean Total Score of 51.7 ± 11.0 compared with 38.8 ± 5.6 among the community sample (p < 0.001) (Table 3). This pattern was consistent across all 8 subdomain scores, though the differences in sleep disordered breathing were smaller with more variability in scores. In addition, 85% of children with FASD attained a Total Score above the clinical cutoff of 41 for sleep dysfunction compared with only 30% of the community sample (p < 0.001). While age, gender, SES, family structure, and presence of ADHD and presence of other chronic medical conditions were found to vary by participant group, none of these factors were found to correlate with CSHQ Total Score (data not shown). Despite an average of an hour less sleep at night in the FASD group (Table 3), both groups showed age-appropriate absence of habitual daytime napping (data not shown).
Among those with FASD, CSHQ Total Scores did not vary greatly by presence or absence of ADHD, ascertained by parental report (Table 4). However, children with comorbid ADHD scored slightly higher on the following subscales: Sleep Duration, Sleep Disordered Breathing, and Daytime Sleepiness. A notably higher percentage of those with comorbid ADHD scored above the cutoff score of 41. In addition, caregivers of children with ADHD reported nearly an hour less sleep per night than those without ADHD.

**Correlation of CSHQ Scores with FASD Severity**

All participants with full FAS or partial FAS (n = 5) attained CSHQ Total Scores above the clinical cutoff of 41. In this relatively small sample, no associations emerged between the CSHQ Total Score and components of FASD diagnosis based on the 4-Digit Code reflecting: (1) growth deficiency (2) facial dysmorphology; (3) central nervous system dysfunction; and (4) level of prenatal alcohol exposure (data not shown).

### Objective Sleep Assessment (Polysomnography)

All 28 children with FASD who had an elevated CSHQ Total Score were referred for a sleep medicine consultation. Ultimately, a sleep medicine evaluation and PSG were completed by 5 children (18%) with an elevated CSHQ Total Score (range: 46-72) (Table 5). Given the small sample size, these data are considered exploratory.

Median age of the 5 children with FASD at time of PSG assessment was 7.5 years (IQR: 6.3, 7.5), and 60% were male (Table 5). All 5 children had a caregiver-reported diagnosis of ADHD. There was a 14.3 ± 8.6 month mean time lapse between CSHQ and PSG, as sleep medicine consultations and PSG occurred based on family and clinical availability. All children tolerated PSG set-up and acquisition.

### Sleep Architecture

There were no overt group differences between the 5 children and published normative values in sleep stage distribution, although ranges varied widely. Fragmented sleep, defined as

---

**Table 3—Children’s Sleep Habits Questionnaire (CSHQ) findings**

<table>
<thead>
<tr>
<th>CSHQ</th>
<th>FASD (n = 33)</th>
<th>Community (n = 418)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Sleep Disturbance Score</td>
<td>51.7 ± 11.0</td>
<td>38.8 ± 5.6</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Percentage above clinical cutoff score (≥ 41)</td>
<td>85%</td>
<td>35%</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Subdomain scores</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bedtime Resistance</td>
<td>9.2 ± 3.3</td>
<td>7.1 ± 1.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Sleep Onset Delay</td>
<td>1.9 ± 0.9</td>
<td>1.3 ± 0.5</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Sleep Duration</td>
<td>4.7 ± 2.1</td>
<td>3.4 ± 0.9</td>
<td>0.001</td>
</tr>
<tr>
<td>Sleep Anxiety</td>
<td>7.0 ± 2.6</td>
<td>4.9 ± 1.5</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Night Wakings</td>
<td>4.9 ± 1.9</td>
<td>3.5 ± 0.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Parasomnias</td>
<td>10.3 ± 2.8</td>
<td>8.1 ± 1.3</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Sleep Disordered Breathing</td>
<td>3.8 ± 1.4</td>
<td>3.3 ± 0.7</td>
<td>0.070</td>
</tr>
<tr>
<td>Daytime Sleepiness</td>
<td>11.2 ± 4.2</td>
<td>9.6 ± 2.8</td>
<td>0.041</td>
</tr>
<tr>
<td>Usual duration of nighttime sleep (h)</td>
<td>9.2 ± 1.5</td>
<td>10.5 ± 0.6</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

FASD, fetal alcohol spectrum disorders.

**Table 4—CSHQ findings by ADHD category among children with FASD**

<table>
<thead>
<tr>
<th>CSHQ</th>
<th>FASD (n = 33)</th>
<th>No AD/HD (n = 7)</th>
<th>AD/HD (n = 25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years</td>
<td>7.5 ± 2.2</td>
<td>7.2 ± 2.7</td>
<td>7.7 ± 2.0</td>
</tr>
<tr>
<td>Male (%)</td>
<td>67</td>
<td>71</td>
<td>68</td>
</tr>
<tr>
<td>Total Sleep Disturbance Score</td>
<td>51.7 ± 11.0</td>
<td>49.0 ± 13.2</td>
<td>51.9 ± 10.4</td>
</tr>
<tr>
<td>Percentage above clinical cutoff score (≥ 41)</td>
<td>85%</td>
<td>57%</td>
<td>92%</td>
</tr>
<tr>
<td>Subdomain scores</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bedtime Resistance</td>
<td>9.2 ± 3.3</td>
<td>9.3 ± 3.8</td>
<td>9.1 ± 3.2</td>
</tr>
<tr>
<td>Sleep Onset Delay</td>
<td>1.9 ± 0.9</td>
<td>1.4 ± 0.8</td>
<td>2.0 ± 0.9</td>
</tr>
<tr>
<td>Sleep Duration</td>
<td>4.7 ± 2.1</td>
<td>3.7 ± 1.1</td>
<td>4.9 ± 2.2</td>
</tr>
<tr>
<td>Sleep Anxiety</td>
<td>7.0 ± 2.6</td>
<td>6.7 ± 2.3</td>
<td>6.8 ± 2.5</td>
</tr>
<tr>
<td>Night Wakings</td>
<td>4.9 ± 1.9</td>
<td>5.0 ± 2.2</td>
<td>4.7 ± 1.7</td>
</tr>
<tr>
<td>Parasomnias</td>
<td>10.3 ± 2.8</td>
<td>10.9 ± 3.3</td>
<td>9.9 ± 2.5</td>
</tr>
<tr>
<td>Sleep Disordered Breathing</td>
<td>3.8 ± 1.4</td>
<td>3.0 ± 0.0</td>
<td>4.0 ± 1.5</td>
</tr>
<tr>
<td>Daytime Sleepiness</td>
<td>11.2 ± 4.2</td>
<td>10.4 ± 4.9</td>
<td>11.6 ± 4.2</td>
</tr>
<tr>
<td>Usual duration of nighttime sleep (h)</td>
<td>9.2 ± 1.5</td>
<td>10.0 ± 0.8</td>
<td>9.1 ± 1.7</td>
</tr>
</tbody>
</table>

CSHQ, Children’s Sleep Habits Questionnaire; ADHD, attention deficit hyperactivity disorder; FASD, fetal alcohol spectrum disorder; Excludes one participant with FASD whose caregiver reported “unknown” on ADHD status.
an elevated total arousal index, was seen among the 5 children with FASD. Median total arousal index was 11.1/h (IQR: 10, 16), and all children with FASD had higher than control group mean values. Respiratory arousal index correlated directly with severity of respiratory disturbances as measured by AHI (estimated slope = 0.74 95% confidence interval (CI): 0.6–0.9). Total arousal index was only moderately associated with AHI (estimated slope = 0.5, 95% CI: -1.1 to 2.1). Thus, not all arousals were directly associated with respiratory disturbances.

Respiratory Events

The median overall AHI was 2.8/h (IQR: 2.2, 4.0), higher than 2 SD above the reported mean AHI in control data. Elevation of AHI in the children with FASD primarily arose from obstructive apneic and hypopneic events, and not central events. All participants with FASD had very mild snoring during PSG. Mean end-tidal CO₂ levels were 45.0 ± 4.5 mm Hg, higher than the reported control group mean of 40.7 ± 4.5 mm Hg. Similar to sleep architecture measures, respiratory parameters showed a wide range of distributions.

Periodic Limb Movements

Periodic limb movements occurred with similar frequency to published control data.

Seizures

No clinical or electroencephalographic seizures were identified among the children with FASD.

Medication Use

Of the 5 children with FASD who underwent PSG, 3 were receiving a single medication and one was receiving multiple medications at the time of study; only one child was medication-free. A medication “washout” was refused by all the caregivers for this clinical evaluation. Families were concerned about the impact of a medication washout on child and family function. Medications were prescribed by non-sleep medicine specialists with the aims of decreasing daytime hyperactivity (amphetamine and non-amphetamine based stimulants), stabilizing mood (valproic acid, buspirone), and/or assisting with sleep initiation/maintenance (clonidine, melatonin) per caregiver report. All medications used are known to affect sleep architecture but not thought to significantly alter respiratory parameters during sleep.

DISCUSSION

Overall prevalence of sleep abnormalities was high among children with FASD, with ~50% to 62% within heterogeneous clinical samples of children

### Table 5—Polysomnography (PSG) findings

<table>
<thead>
<tr>
<th>Subject Summary</th>
<th>Referent PSG (n = 388)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subject</strong></td>
<td><strong>Median; IQR</strong></td>
</tr>
<tr>
<td>Age at PSG study (years)</td>
<td>7.5; 6.3, 7.5</td>
</tr>
<tr>
<td>Gender</td>
<td>60.0% male</td>
</tr>
<tr>
<td>Total Sleep Time (minutes)</td>
<td>468.0; 430.0, 514.0</td>
</tr>
<tr>
<td>Sleep Efficiency (%)</td>
<td>90.0; 77.0, 95.0</td>
</tr>
<tr>
<td>Sleep Latency (minutes)</td>
<td>14.0; 13.0, 32.0</td>
</tr>
<tr>
<td>Stage N1 (%)</td>
<td>5.2; 5.0, 7.0</td>
</tr>
<tr>
<td>Stage N2 (%)</td>
<td>32.0; 29.0, 37.0</td>
</tr>
<tr>
<td>Stage N3 (%)</td>
<td>34.0; 32.0, 35.0</td>
</tr>
<tr>
<td>Stage REM (%)</td>
<td>17.0; 16.9, 24.0</td>
</tr>
<tr>
<td>Wake after sleep onset (%)</td>
<td>5.0; 3.0, 18.0</td>
</tr>
<tr>
<td>Total Arousal Index (events/h)</td>
<td>11.1; 10.0, 16.0</td>
</tr>
<tr>
<td>Respiratory Arousal Index (events/h)</td>
<td>2.0; 1.4, 3.7</td>
</tr>
<tr>
<td>Apnea Hypopnea Index (events/h)</td>
<td>2.8; 2.2, 4.0</td>
</tr>
<tr>
<td>Mean CO₂ (mm Hg)</td>
<td>45.0; 43.0, 47.0</td>
</tr>
<tr>
<td>Periodic Limb Movement Index (events/h)</td>
<td>1.5; 0.0, 1.6</td>
</tr>
</tbody>
</table>

*aRef: Montgomery-Downs, et al.24 SD was not provided in referent population.
and adolescents diagnosed with FASD, ascertained using different diagnostic systems. In addition, this study augments the findings of a very recent systematic study focused on preschoolers, which also uses the validated CSHQ allowing us to directly compare results across groups. The current study expands the age range studied in FASD and adds exploratory data on objective polysomnography to characterize physiologic occurrences during what is reported to be very disturbed sleep in this population.

Interpretation of CSHQ Results
Reports of shortened sleep duration and frequent night wakings in children with FASD may be manifestations of SDB, other primary neurologic sequelae associated with in utero alcohol exposure, or comorbid neuropsychiatric disturbances. In this study, children with FASD scored higher on subdomains involving sleep onset (Bedtime Resistance, Sleep Onset Delay, Sleep Anxiety) and sleep maintenance (Sleep Duration, Night Wakings, Parasomnias). Except for the parasomnia category, this distribution of subjective complaints fits within a larger diagnostic category of pediatric insomnia, defined by a recent consensus statement as “repeated difficulty with sleep initiation, duration, consolidation, or quality that occurs despite age-appropriate time and opportunity for sleep and results in daytime functional impairment for the child and/or family.” All these subjective complaints may contribute to complaints of daytime sleepiness, another elevated subdomain among children with FASD. Similar to findings in a younger cohort, the mean CSHQ Subdomain Score assessing SDB was not appreciably different than the control mean despite preliminary objective evidence from PSG indicating the presence of mild SDB in children with FASD. Caregiver observations are not the best predictors of obstructive sleep apnea, which may account for this discrepancy. This supports the need for both subjective and objective data to best describe clinical sleep abnormalities at this juncture.

Association with ADHD
The clinical symptoms of FASD have some similarities to the diagnostic criteria for ADHD, resulting in likely diagnostic comorbidities. While exact prevalence rates of comorbid ADHD within the general population of FASD are unknown, the current study’s caregiver reported rate of 76% falls within the ranges seen in other clinical samples, finding 60% to 95% of ADHD in persons with FASD. It is important to note that the attentional deficits seen with prenatal alcohol exposure may not have the same neuropsychological profile on detailed testing compared with non-teratogenic ADHD. Unfortunately, these tests are not readily available to most practitioners. Nevertheless, while FASD without symptoms of ADHD is not common, most pediatric practitioners who diagnose ADHD do not assess for any degree of prenatal alcohol exposure. Thus, within the population labeled as ADHD, the rate of FASD is unknown. In studies of children with ADHD, it is possible that some of the observed sleep problems arise through unascertained prenatal alcohol exposure. Therefore, clarifying diagnostic labels and the presence of prenatal alcohol exposure will be important in future studies of sleep problems in clinical samples of both ADHD and FASD.

While a comorbid diagnosis of ADHD in children with FASD may contribute to sleep problems in this population, it is unlikely to be the sole explanation. First, sleep problems are common in general pediatrics and not exclusive to those with ADHD or FASD. Indeed, 35% of subjects in the community sample had CSHQ scores ≥ 41, despite the fact that those on psychostimulant medications (for presumed ADHD) were excluded from the community sample. Second, among the children with FASD in this study, those with and without ADHD still had higher Total Scores than controls, and higher than those with ADHD without known FASD. Meta-analyses of PSG findings in studies of children with a diagnosis of ADHD reported both SDB and an elevation of periodic limb movements; our pilot data in a subset of children with FASD and comorbid ADHD reveal SDB and hypoventilation, but no participant had an elevation in periodic limb movements. While this study was not designed to pinpoint the etiologies of differences between prior findings and this report’s data, prenatal alcohol exposure is a potential culprit.

Etiologic Possibilities for Sleep Problems in Children with FASD
The preliminary PSG data can be used to explore the potential physiologic causes for subjective reports of pediatric insomnia and disrupted sleep in this clinical group, generating hypotheses to be evaluated using larger samples in studies that include carefully defined control groups.

One possible etiology is SDB, based on early evidence of elevated AHI and higher mean end-tidal CO₂ measurements. Breathing irregularities in children with diagnosed FASD may have a physiologic basis. Experimental rodent models of prenatal alcohol exposure describe altered ventilatory responses. Children with FASD have known craniofacial abnormalities leading to narrowed upper airways, and reports show abnormal cerebellar vermis (thought to be involved with respiratory control and muscle coordination) in alcohol-exposed children. Any level of respiratory abnormalities may also result in repeated cortical arousals during sleep, compounding sleep fragmentation.

Another possible etiology for subjective complaints of insomnia lies in frequent cortical arousals leading to sleep fragmentation, presumably unrelated to SDB. This has previously been shown in other studies of prenatally alcohol-exposed infants and children and in animal experiments, with potential mechanisms including potential circadian and sleep homeostatic disturbances as a direct result of alcohol’s teratogenic properties. The median number of cortical arousals in the current small sample undergoing PSG was high compared with controls when respiratory-related arousals were excluded. This suggests the increased occurrence of sleep fragmentation is not attributable only to SDB. It is possible, however, that some cortical arousals labeled as non-respiratory related were actually related to respiratory disturbances not detectable by current techniques.

Limitations
The current study is congruent with previous case series and a very recent systematic study of preschoolers in which high rates of concerning sleep problems were observed in children with FASD. Nevertheless, the data must be interpreted with...
potential study limitations in mind. First, the potential overlap between ADHD and FASD has been addressed but bears further study. Second, only children with clinically significant daytime behavior problems were enrolled into the original intervention study, from which participants in the current study were recruited. However, behavior problems are relatively common among children with FASD, and the children in this study were otherwise representative of the larger FAS DPN clinical database which had similar distribution of CBCL scores. Third, participants with FASD were not only exposed to alcohol before birth, but as a group also had other elevations in prenatal and postnatal psychosocial risk compared with controls, illustrated by lower SES scores and less traditional household/caregiver structures. However, there was still a high prevalence of reported sleep problems among those with FASD and low psychosocial risk (data not shown), indicating that psychosocial risk alone was not likely to have caused the difference between groups. This study was not designed to examine the role of these potential differences on CSHQ, but future studies with larger samples, including matched controls, may be able to do so. Fourth, comparison with the community sample, while quite informative, has limitations because these samples were recruited for different studies. It is unknown whether the community sample includes children with FASD. However, FASD prevalence data would suggest that only about four participants in the community sample would have fallen under the umbrella of FASD. Also, such misclassification of FASD cases as “controls” would have biased the comparison towards the null and away from the results that were actually found in this study. Lastly, the interpretation of PSG data was limited by very small numbers, referral and self-selection bias, and prescribed medications. However, data are in line with a recent study of medication-free preschoolers with FASD.19 These pilot data illustrate the current state of clinical sleep medicine and difficulties in performing PSG in a group of children who are medicated for sleep problems. While these medications are prescribed without an evidence base, to discontinue medications for a study places caregivers and families at risk for recrudescence of worsened behaviors/sleep problems and their sequelae at home.

Future Directions

Though the results of the current study are based on a small sample and are preliminary, they cohere with data from existing basic science and clinical literature. The high prevalence of sleep problems observed in children with FASD suggests that children with FASD should routinely be evaluated for sleep complaints. Sleep problems in this heterogeneous group are likely impacted by multiple factors including the presence of comorbid ADHD, and screening for sleep problems should be done whether or not children show the classic characteristics of the full FAS, with referral to a sleep medicine specialist when appropriate. Sleep problems warrant assessment and treatment, possibly involving medications, as disturbed sleep may worsen the already compromised daytime behavior and adaptive function among children with FASD. An evidence base needs to be created upon which providers make decisions for treatment of sleep problems for those with FASD. Of special importance are study designs that include medication washout, if families can tolerate the functional impact of this procedure. Further elucidations of the mechanisms of alcohol’s teratogenic effects on sleep are needed. Findings from this study highlight the urgency for clinical study of disrupted sleep among the relatively common but often underrecognized population of children with FASD.

REFERENCES


ACKNOWLEDGMENTS

The authors express deep appreciation to the participating families and dedicated clinical and research team of the Washington State Fetal Alcohol Syndrome Diagnostic and Prevention Network (FAS DPN), led by Susan J. Astley, Ph.D. The FAS DPN is the source of participants for this research project. Without the generous participation of families, and the unwavering efforts of the team to better serve individuals with FASD, this research would not have been possible. Work related to this study was performed at Seattle Children’s Hospital and Seattle Children’s Research Institute. Support for this study provided by Seattle Children’s Research Institute Center for Clinical and Translational Research Mentored Scholar Program; U.S. Centers for Disease Control and Prevention, Grant number U01-0000DD038-05; and Seattle Children’s Research Institute.

SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication August, 2011
Submitted in final revised form March, 2012
Accepted for publication March, 2012
Address correspondence to: Maida Lynn Chen, M.D., Seattle Children’s Hospital, 4800 Sand Point Way, NE, MS A-5957, Seattle, WA 98105; Tel: (206) 987-1861; Fax: (206) 987-2639; E-mail: maida.chen@seattlechildrens.org

DISCLOSURE STATEMENT

This was not an industry supported study. The author has indicated no financial conflicts of interest.